N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Harbaum, Lars ^a   Hennigs, Jan K ^a,b   Baumann, Hans J ^a   Lüneburg, Nicole ^a   Griesch, Elisabeth ^a   Bokemeyer, Carsten ^a   Grünig, Ekkehard ^c   Klose, Hans ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CONTROLLED STUDY; ENDARTERECTOMY; FEMALE; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HEMODYNAMIC PARAMETERS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; AGED; BLOOD; CAPILLARY; COMPLICATION; HEMODYNAMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TIME;

AGED; BIOLOGICAL MARKERS; CAPILLARIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84899675111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094263     Document Type: Article

References (37)

1. Rabinovitch M (2012) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122: 4306-4313.
2. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, et al. (2002) Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39: 1214-1219. (Pubitemid 34267428)
3. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, et al. (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161: 487-492. (Pubitemid 30129457)
4. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114: 1417-1431. (Pubitemid 44454562)
5. Cracowski JL, Leuchte HH (2012) The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol 110: 32S-38S.
6. Battistoni A, Rubattu S, Volpe M (2012) Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol 157: 160-168.
7. Hall C (2004) Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 6: 257-260.
8. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr (2008) Biology of the natriuretic peptides. Am J Cardiol 101: 3-8.
9. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, et al. (2003) Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92: 628-631. (Pubitemid 37013426)
10. Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH (2010) The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol 133: 14-23.
11. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, et al. (2006) Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47: 91-97. (Pubitemid 43005170)
12. Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, et al. (2007) NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 29: 737-744. (Pubitemid 46554624)
13. Souza R, Bogossian HB, Humbert M, Jardim C, Rabelo R, et al. (2005) N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 25: 509-513. (Pubitemid 40331182)
14. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, et al. (2006) N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98: 525-529. (Pubitemid 44162883)
15. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, et al. (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129: 1313-1321.
16. Leuchte HH, El Nounou M, Tuerpe JC, Hartmann B, Baumgartner RA, et al. (2007) N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 131: 402-409. (Pubitemid 46280399)
17. Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, et al. (2007) NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 101: 69-75. (Pubitemid 44835241)
18. Bernal V, Pascual I, Esquivias P, Garcia-Gil A, Mateo JM, et al. (2009) N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension. Transplant Proc 41: 987-988.
19. Mathai SC, Bueso M, Hummers LK, Boyce D, Lechtzin N, et al. (2010) Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 35: 95-104.
20. Mauritz GJ, Rizopoulos D, Groepenhoff H, Tiede H, Felix J, et al. (2011) Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 108: 1645-1650.
21. Frantz RP, McDevitt S, Walker S (2012) Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. J Heart Lung Transplant 31: 811-816.
22. Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, et al. (2012) Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J 39: 104-111.
23. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, et al. (2012) The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 39: 589-596.
24. Suntharalingam J, Goldsmith K, Toshner M, Doughty N, Sheares KK, et al. (2007) Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir Med 101: 2254-2262. (Pubitemid 47484789)
25. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493-2537.
26. ATS statement (2002). Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111-117.
27. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, et al. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147.
28. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R (2005) What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 26: 2269-2276. (Pubitemid 41541390)
29. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, et al. (2012) The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 141: 354-362.
30. Haddad F, Fuh E, Peterson T, Skhiri M, Kudelko KT, et al. (2011) Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Card Fail 17: 533-539.
31. Mielniczuk LM, Chandy G, Stewart D, Contreras-Dominguez V, Haddad H, et al. (2012) Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. Congest Heart Fail 18: 151-157.
32. Sato Y (2013) Diagnostic and prognostic property of NT-proBNP in patients with renal dysfunction. Journal of cardiology 61: 446-447.
33. van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, et al. (2006) Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 48: 1621-1627. (Pubitemid 44528169)
34. Horii M, Matsumoto T, Uemura S, Sugawara Y, Takitsume A, et al. (2013) Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. Journal of cardiology 61: 410-416.
35. Gan CT, McCann GP, Marcus JT, van Wolferen SA, Twisk JW, et al. (2006) NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 28: 1190-1194. (Pubitemid 44883855)
36. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, et al. (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62: D73-81.
37. Humbert M (2010) Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev 19: 59-63.